Check-Cap Ltd (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan, an ingestible capsule for the prevention of colorectal cancer, announced yesterday its financial results for the first quarter ended 31 March 2019.
The company reported research and development expenses at USD2.3m for the three months ended 31 March 2019, compared to USD1.6m for the same period in 2018.
The firm posted an operating loss of USD3.2m for the three months ended 31 March 2019, as against an operating loss of USD2.1m for the same period in 2018.
Pharmazz Inc begins Phase III trial of PMZ-1620 in cerebral ischemic stroke patients
Orphazyme completes enrolment for phase 3 trial evaluating arimoclomol in ALS
Lupus Therapeutics names new director
PHAR names new vice president for Health Economics and Outcomes Research